

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A method ~~for the~~ of treatment of ~~a symptom of a disorder or condition associated with sensorimotor gating deficits, which comprises comprising~~ administering to a mammal in need of the treatment for at least one symptom of a disorder or condition associated with sensorimotor gating deficits an effective amount of an ~~alfa~~alpha-2-adrenoceptor antagonist, or a pharmaceutically acceptable ester or salt thereof, said ~~wherein the~~ alfaalpha-2-adrenoceptor antagonist being is selective for the ~~alfa~~alpha-2C-adrenoceptor subtype.
2. (Currently Amended) A method according to claim 1, wherein the at least one symptom is chosen from hallucination, delusion, parathymia, agitation, psychotic cognitive impairment, social withdrawal, ~~and/or~~ withdrawal symptom associated with cessation of cigarette smoking or alcohol or drug abuse.
3. (Currently Amended) A method according to claim 1, wherein the at least one symptom is hallucination.
4. (Currently Amended) A method according to claim 1, wherein the at least one symptom is delusion.
5. (Currently Amended) A method according to claim 1, wherein the at least one symptom is parathymia.
6. (Currently Amended) A method according to claim 1, wherein the at least one symptom is agitation[.,].

7. (Currently Amended) A method according to claim 1, wherein the at least one symptom is psychotic cognitive impairment.

8. (Currently Amended) A method according to claim 1, wherein the at least one symptom is social withdrawal.

9. (Previously Presented) A method according to claim 1, wherein the disorder or condition is schizophrenia, obsessive compulsive disorder, Tourette's syndrome, blepharospasm and other focal dystonias, temporal lobe epilepsy with psychosis, drug-induced psychosis, Huntington's disease, Parkinson's disease, disorder caused by fluctuation of the levels of sex hormones, or panic disorder.

10. (Previously Presented) A method according to claim 1, wherein the disorder is schizophrenia.

11. (Previously Presented) A method according to claim 1, wherein the disorder is obsessive compulsive disorder.

12. (Previously Presented) A method according to claim 1, wherein the disorder is Tourette's syndrome.

13. (Previously Presented) A method according to claim 1, wherein the administering of the alpha2-adrenoceptor antagonist selective for the alpha2C-adrenoceptor is combined with the administering of other psychiatric medication.

14. (Previously Presented) A method according to claim 1, wherein the mammal is a human.

15. (Previously Presented) A method according to claim 1, wherein the mammal is an animal.

16. (New) A method of treatment comprising administering to a mammal in need of treatment for at least one symptom of a disorder or condition associated with sensorimotor gating deficits an effective amount of acridin-9-yl-[4-(4-methylpiperazin-1-yl)-phenyl]amine.

17. (New) A method according to claim 16, wherein the at least one symptom is psychotic cognitive impairment.

18. (New) A method according to claim 16, wherein the disorder or condition is schizophrenia.